Press Releases

Filters
October 3, 2017

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…

Read more
July 25, 2017

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Read more
June 30, 2017

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…

Read more
June 20, 2017

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Read more
June 15, 2017

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Read more
June 1, 2017

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

Read more
May 24, 2017

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

Read more
March 23, 2017

Debiopharm International uses cutting-edge ClinTrial App mobile application from ClinOne in clinical study

Read more
March 10, 2017

Debiopharm International SA Appeals to the Supreme Court regarding Towa Pharmaceutical Co., Ltd. case

Read more